NeuroBo Pharmaceuticals, Inc. Annual Share-based Payment Arrangement, Expense in USD from 2014 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
NeuroBo Pharmaceuticals, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2014 to 2023.
  • NeuroBo Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $139K, a 19.2% decline year-over-year.
  • NeuroBo Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $478K, a 40.6% increase year-over-year.
  • NeuroBo Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $222K, a 74% decline from 2022.
  • NeuroBo Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $854K, a 29% increase from 2021.
  • NeuroBo Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $662K, a 5.29% decline from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $222K -$632K -74% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-28
2022 $854K +$192K +29% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-28
2021 $662K -$37K -5.29% Jan 1, 2021 Dec 31, 2021 10-K 2022-03-31
2020 $699K +$581K +492% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-31
2019 $118K -$4.01M -97.1% Jan 1, 2019 Dec 31, 2019 10-K 2021-04-15
2018 $4.13M -$1.14M -21.7% Jan 1, 2018 Dec 31, 2018 10-K 2019-03-18
2017 $5.27M +$3.56M +207% Jan 1, 2017 Dec 31, 2017 10-K 2019-03-18
2016 $1.72M +$1.43M +505% Jan 1, 2016 Dec 31, 2016 10-K 2019-03-18
2015 $284K +$231K +436% Jan 1, 2015 Dec 31, 2015 10-K 2018-03-20
2014 $53K Jan 1, 2014 Dec 31, 2014 10-K 2017-03-21
* An asterisk sign (*) next to the value indicates that the value is likely invalid.